Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.
The American Society of Clinical Oncology (ASCO) recently updated its clinical guidelines for advanced non-small cell lung cancer (NSCLC) so that oncologists can select the most appropriate treatment for patients. Treatments ... Read more
The U.S. Food and Drug Administration (FDA) is considering adding the risk of eye toxicities that could cause vision loss and retinal detachment on the labels of Bristol-Myers Squibb’s Opdivo ... Read more
Celgene Corporation has entered a strategic collaboration with BeiGene to develop and commercialize its PD-1 inhibitor BGB-A317, an immunotherapy primarily aimed at treating solid tumors, in the U.S., Europe, Japan and much of the ... Read more
Jounce Therapeutics’ JTX-2011 was well-tolerated by patients with advanced solid tumors in the Phase 1/2 ICONIC clinical trial (NCT02904226), alone or in combination with Opdivo (nivolumab), supporting advancement of ... Read more
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab) to treat locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer. The approval, ... Read more